HEPZATO — Topline data
Late 2027
The trial's primary endpoint, hPFS, is anticipated to read out by the end of 2027, while OS, a secondary endpoint, is expected in 2028.Source filing
DCTH biotech catalysts & pipeline
DELCATH SYSTEMS INC · Data as of 2026-09-08
Upcoming catalysts
melphalan for Injection/Hepatic Delivery System — Topline data
Late 2027
The trial's primary endpoint, hPFS, is anticipated to read out by the end of 2027, while OS, a secondary endpoint, is expected in 2028.Source filing
melphalan for Injection/Hepatic Delivery System — Topline data
2028
The trial's primary endpoint, hPFS, is anticipated to read out by the end of 2027, while OS, a secondary endpoint, is expected in 2028.Source filing
HEPZATO — Topline data
Late 2028
The trial's primary endpoint, hPFS, is anticipated to read out by the end of 2028, while results for OS, a secondary endpoint, is expected in 2029.Source filing
HEPZATO — Topline data
in 2029
The trial's primary endpoint, hPFS, is anticipated to read out by the end of 2028, while results for OS, a secondary endpoint, is expected in 2029.Source filing
HEPZATO — Topline data
mid 2029
Primary endpoint = hPFS anticipated mid 2029; OS expected in 2030.Source filing